Compass Therapeutics (NASDAQ:CMPX) Given “Buy” Rating at Guggenheim

Guggenheim reissued their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX) in a research report released on Tuesday morning,Benzinga reports.

CMPX has been the topic of a number of other research reports. HC Wainwright restated a “buy” rating and issued a $24.00 price objective on shares of Compass Therapeutics in a report on Monday. Jefferies Financial Group boosted their price target on shares of Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, February 10th. Piper Sandler began coverage on shares of Compass Therapeutics in a report on Wednesday, February 19th. They issued an “overweight” rating and a $12.00 price objective for the company. Wedbush reissued an “outperform” rating and issued a $8.00 target price on shares of Compass Therapeutics in a research note on Tuesday, April 1st. Finally, Leerink Partners upgraded Compass Therapeutics from a “market perform” rating to an “outperform” rating and upped their price target for the company from $4.00 to $6.00 in a research report on Wednesday, April 2nd. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Compass Therapeutics has an average rating of “Buy” and a consensus target price of $13.38.

Compass Therapeutics Stock Up 11.2 %

CMPX opened at $1.98 on Tuesday. The company has a market cap of $273.80 million, a PE ratio of -5.35 and a beta of 1.40. Compass Therapeutics has a twelve month low of $0.77 and a twelve month high of $4.08. The company has a 50-day moving average price of $2.30 and a 200 day moving average price of $2.09.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01). As a group, sell-side analysts expect that Compass Therapeutics will post -0.36 earnings per share for the current year.

Insider Activity at Compass Therapeutics

In other Compass Therapeutics news, insider Jonathan Anderman purchased 20,000 shares of the firm’s stock in a transaction dated Monday, April 7th. The shares were acquired at an average price of $1.54 per share, with a total value of $30,800.00. Following the purchase, the insider now directly owns 21,000 shares in the company, valued at approximately $32,340. This trade represents a 2,000.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Carl L. Gordon sold 3,571,428 shares of the stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total value of $5,678,570.52. The disclosure for this sale can be found here. 28.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Compass Therapeutics

Several large investors have recently made changes to their positions in CMPX. SG Americas Securities LLC raised its position in Compass Therapeutics by 138.2% in the first quarter. SG Americas Securities LLC now owns 940,784 shares of the company’s stock valued at $1,787,000 after purchasing an additional 545,767 shares during the period. Simplicity Wealth LLC acquired a new stake in shares of Compass Therapeutics in the first quarter valued at $88,000. Squarepoint Ops LLC purchased a new stake in shares of Compass Therapeutics in the 4th quarter valued at $35,000. Tang Capital Management LLC lifted its stake in Compass Therapeutics by 225.4% during the 4th quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company’s stock worth $8,555,000 after acquiring an additional 4,087,005 shares in the last quarter. Finally, ProShare Advisors LLC boosted its holdings in Compass Therapeutics by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 28,722 shares of the company’s stock valued at $42,000 after acquiring an additional 9,451 shares during the period. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.